Skip to content

Effectiveness of oxymetazoline in bronchoscopy in patients with turbinate hypertrophy

Effectiveness of oxymetazoline in bronchoscopy in patients with turbinate hypertrophy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077642
Enrollment
Unknown
Registered
2023-11-15
Start date
2023-11-15
Completion date
Unknown
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

turbinate hypertrophy

Interventions

group A:Nostrils receive oxymetazoline spray
group B:Nostrils receive saline spray
group C:Blank control group receiving no intervention

Sponsors

Chaohu Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) indication for fiberoptic bronchoscopy; (2) diagnosis of turbinate hypertrophy by an otolaryngologist.

Exclusion criteria

Exclusion criteria: (1) Age 85 years; (2) Comorbidities such as severe respiratory failure, decompensated heart failure, and severe hypertension (systolic blood pressure (BP) > 180 mmHg or diastolic BP > 100 mmHg); (3) Requirement for general anesthesia; and (4) Refusal of consent. (5) Complete nasal obstruction.

Design outcomes

Primary

MeasureTime frame
Tracheoscopic arrival time at the vocal folds;

Secondary

MeasureTime frame
Scoring of ease of tracheoscopy through the nasal cavity;Facial Pain Scale scores as rated by an assistant;Patient-rated nasal pain scores;Operator-rated nasal mucosal trauma score;

Countries

China

Contacts

Public ContactZhang Jie

Chaohu Hospital of Anhui Medical University

963186951@qq.com+86 136 3564 1420

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 28, 2026